The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
Crohn’s disease (CD) and ulcerative colitis (UC), the two main forms of inflammatory bowel disease (IBD), are chronic, systemic autoimmune diseases. As the incidence of IBD rapidly increases in Asia, increasing attention has been paid to developing additional treatment strategies. Presently, the end...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222014706 |
| _version_ | 1811178905305874432 |
|---|---|
| author | Yu Chen Guolin Zhang Yuewen Yang Shuangshuang Zhang Haozheng Jiang Kang Tian Arenbaoligao Dapeng Chen |
| author_facet | Yu Chen Guolin Zhang Yuewen Yang Shuangshuang Zhang Haozheng Jiang Kang Tian Arenbaoligao Dapeng Chen |
| author_sort | Yu Chen |
| collection | DOAJ |
| description | Crohn’s disease (CD) and ulcerative colitis (UC), the two main forms of inflammatory bowel disease (IBD), are chronic, systemic autoimmune diseases. As the incidence of IBD rapidly increases in Asia, increasing attention has been paid to developing additional treatment strategies. Presently, the end point of therapy is achieving clinical and endoscopic remission through the blockade of inflammatory cascades. Recent studies have shown that monoclonal antibodies (mAbs) use for precise molecular targeting of inflammatory pathways has a promising effect on IBD, especially moderate-to-severe CD and UC. Since the 1997 report on the use of infliximab (a monoclonal antibody against tumor necrosis factor alpha [TNF-α]) in patients with CD, mAbs have expanded therapeutic options and have also complicated initial management options and subsequent treatment. This review comprehensively summarizes the clinical reports and studies related to the use of mAbs for the treatment of IBD in Asian countries and regions in recent years thus demonstrating the current status of mAbs use in Asia. In addition, the differences in the use of mAbs for the treatment of IBD between the Asia and the West are expounded. Ultimately, it is hoped that this review will provide new insights and a scientific basis for the clinical application of mAbs. |
| first_indexed | 2024-04-11T06:25:52Z |
| format | Article |
| id | doaj.art-0a237dcd581f4322977bf216b23f0946 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-11T06:25:52Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-0a237dcd581f4322977bf216b23f09462022-12-22T04:40:21ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-01-01157114081The treatment of inflammatory bowel disease with monoclonal antibodies in AsiaYu Chen0Guolin Zhang1Yuewen Yang2Shuangshuang Zhang3Haozheng Jiang4Kang Tian5 Arenbaoligao6Dapeng Chen7Dalian Medical University, Dalian, ChinaDalian Medical University, Dalian, ChinaDalian Medical University, Dalian, ChinaDalian Medical University, Dalian, ChinaDepartment of Joint and Sports Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of Joint and Sports Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDalian Medical University, Dalian, China; Corresponding authors.Dalian Medical University, Dalian, China; Corresponding authors.Crohn’s disease (CD) and ulcerative colitis (UC), the two main forms of inflammatory bowel disease (IBD), are chronic, systemic autoimmune diseases. As the incidence of IBD rapidly increases in Asia, increasing attention has been paid to developing additional treatment strategies. Presently, the end point of therapy is achieving clinical and endoscopic remission through the blockade of inflammatory cascades. Recent studies have shown that monoclonal antibodies (mAbs) use for precise molecular targeting of inflammatory pathways has a promising effect on IBD, especially moderate-to-severe CD and UC. Since the 1997 report on the use of infliximab (a monoclonal antibody against tumor necrosis factor alpha [TNF-α]) in patients with CD, mAbs have expanded therapeutic options and have also complicated initial management options and subsequent treatment. This review comprehensively summarizes the clinical reports and studies related to the use of mAbs for the treatment of IBD in Asian countries and regions in recent years thus demonstrating the current status of mAbs use in Asia. In addition, the differences in the use of mAbs for the treatment of IBD between the Asia and the West are expounded. Ultimately, it is hoped that this review will provide new insights and a scientific basis for the clinical application of mAbs.http://www.sciencedirect.com/science/article/pii/S0753332222014706Inflammatory bowel diseaseUlcerative colitisCrohn’s diseaseMonoclonal antibodiesEffectivenessSafety |
| spellingShingle | Yu Chen Guolin Zhang Yuewen Yang Shuangshuang Zhang Haozheng Jiang Kang Tian Arenbaoligao Dapeng Chen The treatment of inflammatory bowel disease with monoclonal antibodies in Asia Biomedicine & Pharmacotherapy Inflammatory bowel disease Ulcerative colitis Crohn’s disease Monoclonal antibodies Effectiveness Safety |
| title | The treatment of inflammatory bowel disease with monoclonal antibodies in Asia |
| title_full | The treatment of inflammatory bowel disease with monoclonal antibodies in Asia |
| title_fullStr | The treatment of inflammatory bowel disease with monoclonal antibodies in Asia |
| title_full_unstemmed | The treatment of inflammatory bowel disease with monoclonal antibodies in Asia |
| title_short | The treatment of inflammatory bowel disease with monoclonal antibodies in Asia |
| title_sort | treatment of inflammatory bowel disease with monoclonal antibodies in asia |
| topic | Inflammatory bowel disease Ulcerative colitis Crohn’s disease Monoclonal antibodies Effectiveness Safety |
| url | http://www.sciencedirect.com/science/article/pii/S0753332222014706 |
| work_keys_str_mv | AT yuchen thetreatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT guolinzhang thetreatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT yuewenyang thetreatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT shuangshuangzhang thetreatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT haozhengjiang thetreatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT kangtian thetreatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT arenbaoligao thetreatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT dapengchen thetreatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT yuchen treatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT guolinzhang treatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT yuewenyang treatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT shuangshuangzhang treatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT haozhengjiang treatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT kangtian treatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT arenbaoligao treatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia AT dapengchen treatmentofinflammatoryboweldiseasewithmonoclonalantibodiesinasia |